CLDX Celldex Therapeutics, Inc.

Nasdaq celldex.com


$ 26.30 $ -0.46 (-1.72 %)    

Thursday, 23-Oct-2025 17:13:32 EDT
QQQ $ 611.70 $ 5.09 (0.84 %)
DIA $ 467.20 $ 1.51 (0.32 %)
SPY $ 672.21 $ 3.96 (0.59 %)
TLT $ 91.38 $ -0.63 (-0.68 %)
GLD $ 378.90 $ 1.51 (0.4 %)
$ 26.26
$ 26.80
$ 20.40 x 10
$ 27.49 x 5
$ 25.97 - $ 26.90
$ 14.40 - $ 29.38
822,124
na
1.74B
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-07-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-07-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-14-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-23-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mizuho-initiates-coverage-on-celldex-therapeutics-with-outperform-rating-announces-price-target-of-48

Mizuho analyst Joseph Catanzaro initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Outperform rating and announ...

 barclays-initiates-coverage-on-celldex-therapeutics-with-underweight-rating-announces-price-target-of-25

Barclays analyst Etzer Darout initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Underweight rating and announc...

 canaccord-genuity-maintains-buy-on-celldex-therapeutics-maintains-62-price-target

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $62 price target.

 wells-fargo-maintains-overweight-on-celldex-therapeutics-lowers-price-target-to-38

Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target...

 citigroup-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-48

Citigroup analyst David Lebowitz maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $5...

 celldex-therapeutics-pulls-plug-on-eosinophilic-esophagitis-investigational-drug-as-data-falls-short

Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but...

 canaccord-genuity-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-62

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target fr...

 hc-wainwright--co-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-42

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the pric...

 celldex-reports-phase-2-topline-results-for-barzolvolimab-in-eosinophilic-esophagitis-says-study-met-primary-endpoint-demonstrating-barzolvolimabs-ability-to-potently-deplete-mast-cells-in-gastrointestinal-tract

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolv...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION